Latest Biotech News

Roche used its diagnostics day to outline a strategy to become an end-to-end oncology solutions provider, spanning early detection through therapy selection and monitoring. Executives highlighted...

Eli Lilly pointed to lower-dose and maintenance approaches for its obesity medicines, framing dose reduction as a potential option for sustaining weight loss while managing safety and cost...

A clinical program presented at ECO2026 and published in Nature Medicine reported that sustained weight loss appears achievable by moving patients from injectable obesity drugs to daily oral...

Isomorphic Labs closed a $2.1 billion Series B, one of the largest rounds in biotech history, to expand its AI-driven drug design engine and accelerate pipeline development. The round was led by...

Bristol Myers Squibb and Hengrui Pharma entered a broad drug research collaboration covering 13 early development programs across oncology, hematology, and immunology. BMS will pay $600 million...

Data from the MYTHIC trial presented at a conference setting reported a 60% objective response rate at the proposed recommended phase 2 dose (RP2D) in patients with CCNE1-amplified...

10x Genomics and Harvard University sued Element Biosciences over alleged infringement tied to Element’s AVITI24 multiomics platform and related workflows. The complaint asserts infringement of...

Kyverna Therapeutics began a rolling submission to the FDA for its autoimmune CAR-T program miv-cel after additional natural history analysis requested by the agency. The company positioned...

FDA Commissioner Marty Makary resigned, ending a turbulent tenure that included efforts to speed drug development and repeated turnover in senior roles. President Trump confirmed Makary’s...

Bristol Myers Squibb and Hengrui Pharma launched a global research pact spanning 13 early development programs across oncology, hematology and immunology, with deal terms reported as up to $15.2...

The European Parliament and Council provisionally approved the Critical Medicines Act, advancing an EU-wide framework intended to strengthen supply chains for medicines deemed critical. The...

Roche outlined a strategy to become an end-to-end oncology solutions provider by combining diagnostic instruments, testing workflows and new capabilities via acquisitions. At its diagnostics day,...

Isomorphic Labs, the Alphabet-backed AI biotech focused on drug design, closed a $2.1 billion Series B round to scale its unified drug discovery engine. Thrive Capital led the round with...

LiquidCell Dx began building an evidence base for LiquidTME, a cell-free DNA methylation profiling assay designed to predict response to immune checkpoint inhibitors by characterizing tumor...

Researchers at Washington University School of Medicine reported Phase I/II multicenter results in Nature Medicine showing that CRISPR-Cas9 deletion of CD33 from donor cells can help reduce...

Data presented from the MYTHIC trial showed activity for lunresertib plus zedoresertib in platinum-resistant ovarian cancer, with response rates highest in a biomarker-defined subgroup. For...

The U.S. Department of Commerce issued procedures giving companies 30 days to submit company-specific onshoring plans to qualify for agreements tied to Section 232 biopharma tariffs. The notice...

Capsida Biotherapeutics said it still has no answers in its investigation into the death of a child in a gene therapy trial last September. The company reported that efforts were blocked because...

Isomorphic Labs closed a $2.1 billion Series B, underlining how quickly Alphabet-linked assets are moving from model-building to clinical execution. The London-based AI biotech said Thrive Capital...

Bristol Myers Squibb and Hengrui Pharma expanded their China-centric collaboration, agreeing to a broad deal covering 13 early-stage programs. The pact, structured as a “biobucks” arrangement,...